Paper highlights best practices for omega-3 clinical trials with cardiovascular outcomes
SALT LAKE CITY, Utah, February 2, 2016 – A paper published this week in the journal Prostaglandins, Leukotrienes and Essential Fatty Acids sheds new light on recent neutral studies questioning the benefits of omega-3s for heart health. The paper titled, "Conducting Omega-3 Clinical Trials with Cardiovascular Outcomes: Proceedings of a Workshop Held at ISSFAL 2014," identifies experimental design issues in recent studies that have not demonstrated significant effects of EPA and DHA omega-3s on cardiovascular disease outcomes and suggests that it is too early to conclude that EPA and DHA do not provide cardiovascular health benefits.
The data from the paper, which was presented at a workshop sponsored by the Global Organization for EPA and DHA Omega-3s (GOED) at the International Society for the Study of Fatty Acids and Lipids 2014 Congress, found that recent neutral findings may have been due to a number of design issues, rather than a lack of substantiated clinical benefits in cardiovascular disease. The issues include such things as:
- aggressive cardiovascular drug treatment overshadowing the benefits of long-chain omega-3s
- high background long-chain omega-3 intake at study initiation
- too few subjects in the study
- treatment duration too short
- insufficient LC omega-3 dosage
- increase in omega-6 fatty acid intake during the study
- failure to assess the LC omega-3 status of the subjects prior to and during treatment
- lack of clarity concerning which mechanisms were expected to produce benefits
"It's very important that researchers consider these issues when designing clinical trials and discussing the results of studies that show non-significant effects of omega-3s in cardiovascular outcomes," said Dr. Harry Rice, vice president of regulatory and scientific affairs for GOED and lead author on the paper. "Some of these studies have been heavily publicized in mainstream media, often without the necessary context. This leads consumers to believe omega-3s are not heart healthy and to possibly eat less fish or stop taking an omega-3 supplement."
It is possible the recent studies show neutral results for omega-3 intake because there are no associated cardiovascular benefits, but with multiple large-scale clinical trials ongoing in this area, it is premature to conclude omega-3s do not reduce cardiovascular disease risk. The existing body of gold-standard research showing omega-3s may reduce cardiovascular death risk, maintain healthy blood pressure and improve triglyceride levels also makes it difficult to conclude that EPA and DHA consumption does not contribute to a healthy heart.
For more information about the Global Organization for EPA and DHA Omega-3s, visit GOEDOmega3s.com.
GOED is an association of the world's finest processors, refiners, manufacturers, distributors, marketers, retailers and supporters of products containing Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) omega-3 fatty acids. The organization's objectives are to educate consumers about the health benefits of EPA/DHA, and work with government groups, the healthcare community and the industry, while setting high standards for its business sector. GOED and its members are committed to personal integrity, ethical corporate behavior, public safety and quality assurance. For more information, visit http://www.goedomega3.com.